Shopping Cart 0
Cart Subtotal
USD 0

Hikma Pharmaceuticals Plc (HIK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc (HIK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16

Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17

Venture Financing 18

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18

Prognos Health Raises USD20.5 Million in Series C Financing 20

Partnerships 21

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21

Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22

Hikma Pharma Forms Joint Venture With Midroc Pharma 23

Venture Life Enters into Distribution Agreement with Hikma Pharma 24

Licensing Agreements 25

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25

Hikma Pharma Enters into Licensing Agreement with Rovi 26

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30

Hikma Pharma Enters into Licensing Agreement with Octapharma 31

Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32

Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33

Hikma Pharma Enters into Licensing Agreement with Azanta 34

Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35

Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36

Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37

Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38

Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39

Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40

Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41

Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42

Debt Offering 43

Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43

Asset Transactions 44

Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44

Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45

Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46

Acquisition 47

Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47

Hikma Pharma to Acquire EIMC United Pharma 49

Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50

Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52

Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53

Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For USD 42 Million 54

Hikma Pharmaceuticals Plc-Key Competitors 55

Hikma Pharmaceuticals Plc-Key Employees 56

Hikma Pharmaceuticals Plc-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Joint Venture 58

Recent Developments 59

Financial Announcements 59

Aug 15, 2018: Hikma Pharmaceuticals: Half-year report 59

Mar 14, 2018: Hikma reports 2017 full year results 64

Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet 65

Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency 66

Corporate Communications 67

Jun 04, 2018: Hikma Appoints Henriette Nielsen As Chief Transformation Officer 67

Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma 68

Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D 69

Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business 70

Other Significant Developments 71

May 03, 2017: Hikma Changes Registered Office 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16

Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18

Prognos Health Raises USD20.5 Million in Series C Financing 20

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21

Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22

Hikma Pharma Forms Joint Venture With Midroc Pharma 23

Venture Life Enters into Distribution Agreement with Hikma Pharma 24

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25

Hikma Pharma Enters into Licensing Agreement with Rovi 26

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30

Hikma Pharma Enters into Licensing Agreement with Octapharma 31

Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32

Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33

Hikma Pharma Enters into Licensing Agreement with Azanta 34

Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35

Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36

Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37

Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38

Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39

Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40

Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41

Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42

Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43

Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44

Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45

Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46

Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47

Hikma Pharma to Acquire EIMC United Pharma 49

Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50

Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52

Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53

Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For USD 42 Million 54

Hikma Pharmaceuticals Plc, Key Competitors 55

Hikma Pharmaceuticals Plc, Key Employees 56

Hikma Pharmaceuticals Plc, Subsidiaries 57

Hikma Pharmaceuticals Plc, Joint Venture 58

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Hikma Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Hikma Pharmaceuticals Plc (Hikma) develops, manufactures and markets branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular, diabetes, central nervous system (CNS), cancer, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma Pharmaceuticals sells its products through sales and marketing teams and representatives to leading wholesalers, pharmacy chains, governments and hospital purchasing organizations. The company markets its products in the UK, the Middle East and North Africa (MENA) and Europe and Rest of the World (ROW). Hikma Pharmaceuticals is headquartered in London, the UK.

Hikma Pharmaceuticals Plc (HIK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16

Asset Purchase 16

Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16

Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17

Venture Financing 18

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18

Prognos Health Raises USD20.5 Million in Series C Financing 20

Partnerships 21

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21

Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22

Hikma Pharma Forms Joint Venture With Midroc Pharma 23

Venture Life Enters into Distribution Agreement with Hikma Pharma 24

Licensing Agreements 25

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25

Hikma Pharma Enters into Licensing Agreement with Rovi 26

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30

Hikma Pharma Enters into Licensing Agreement with Octapharma 31

Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32

Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33

Hikma Pharma Enters into Licensing Agreement with Azanta 34

Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35

Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36

Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37

Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38

Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39

Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40

Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41

Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42

Debt Offering 43

Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43

Asset Transactions 44

Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44

Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45

Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46

Acquisition 47

Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47

Hikma Pharma to Acquire EIMC United Pharma 49

Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50

Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52

Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53

Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For USD 42 Million 54

Hikma Pharmaceuticals Plc-Key Competitors 55

Hikma Pharmaceuticals Plc-Key Employees 56

Hikma Pharmaceuticals Plc-Locations And Subsidiaries 57

Head Office 57

Other Locations & Subsidiaries 57

Joint Venture 58

Recent Developments 59

Financial Announcements 59

Aug 15, 2018: Hikma Pharmaceuticals: Half-year report 59

Mar 14, 2018: Hikma reports 2017 full year results 64

Aug 17, 2017: Hikma Delivers Stable Profitability and Strong Cash Generation In H1 and Maintains a Solid Balance Sheet 65

Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency 66

Corporate Communications 67

Jun 04, 2018: Hikma Appoints Henriette Nielsen As Chief Transformation Officer 67

Feb 20, 2018: Sigurdur Olafsson appointed Chief Executive Officer of Hikma 68

Jan 15, 2018: Hikma Appoints Dr. Surendera Tyagi as Group Chief Scientific Officer and Global Head of R&D 69

Jun 26, 2017: Hikma Pharmaceuticals Announces Leadership and Organisational Changes to US Business 70

Other Significant Developments 71

May 03, 2017: Hikma Changes Registered Office 71

Appendix 72

Methodology 72

About GlobalData 72

Contact Us 72

Disclaimer 72


List Of Figure

List of Figures

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Hikma Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Hikma Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12

Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Hikma Pharma Acquires Six Products from Boehringer Ingelheim 16

Hikma Pharma to Acquire Portfolio of Six Injectable Products from Pfizer 17

Reciprocal Labs (Propeller Health) Secures USD20 Million in Venture Funding 18

Prognos Health Raises USD20.5 Million in Series C Financing 20

Hikma Pharma Enters into Distribution Agreement with Eisai for Fycompa 21

Hikma Pharma Enters Into Co-Development Agreement With AUB-NCC For Anticancer Drugs 22

Hikma Pharma Forms Joint Venture With Midroc Pharma 23

Venture Life Enters into Distribution Agreement with Hikma Pharma 24

Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 25

Hikma Pharma Enters into Licensing Agreement with Rovi 26

Hikma Pharma Enters into Licensing Agreement with Celltrion and Celltrion Healthcare 27

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 28

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 29

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 30

Hikma Pharma Enters into Licensing Agreement with Octapharma 31

Hikma Pharma Extends its Distribution Agreement with Basilea Pharma 32

Hikma Pharma Enters into Licensing Agreement with Vitabiotics 33

Hikma Pharma Enters into Licensing Agreement with Azanta 34

Hikma Pharma Enters into Licensing Agreement with SK Chemicals 35

Hikma Pharma Enters into Licensing Agreement with Vectura Group for VR730 36

Hikma Pharma Enters into Licensing and Supply Agreement with GP Pharm 37

Hikma Pharma Enters Into Licensing Agreement With Theravance For Vibativ 38

Hikma Pharma Enters Into Licensing Agreement With Dance Biopharm For Inhaled Insulin Product 39

Sinclair IS Pharma Enters Into Licensing Agreement With Hikma Pharma For Flammacerium 40

Hikma Pharma Enters Into Licensing Agreement With EffRx Pharma For Binosto 41

Hikma Pharma Enters Into Licensing Agreement With GP Pharm For Lutrate 1 Month 42

Hikma Pharma Prices Private Placement of Bonds Due 2020 for USD500 Million 43

Amphastar Pharma Acquires 14 ANDAs from Hikma Pharma for USD4 Million 44

Renaissance Pharma Plans to Acquire Assets of Two Generic Drugs from Hikma Pharma 45

Unimark Remedies Plans to Acquire US Marketing Rights to Flecainide from Hikma Pharma 46

Hikma Pharma Acquires Roxane Labs and Boehringer Ingelheim Roxane from Boehringer Ingelheim Pharma 47

Hikma Pharma to Acquire EIMC United Pharma 49

Hikma Pharma Completes Acquisition of Bedford Labs from Ben Venue Labs for USD300 Million 50

Hikma Pharma Plans To Acquire Pharma Company In Middle East And Africa 52

Hikma Pharm Acquires Egyptian Company for Pharma & Chemical for USD22 Million 53

Hikma Pharma Completes Acquisition Of Additional 30.2% Stake In Promopharm For USD 42 Million 54

Hikma Pharmaceuticals Plc, Key Competitors 55

Hikma Pharmaceuticals Plc, Key Employees 56

Hikma Pharmaceuticals Plc, Subsidiaries 57

Hikma Pharmaceuticals Plc, Joint Venture 58

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Hikma Pharmaceuticals Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.